To enhance the stimulation efficiency of in vivo DC targeting mRNA delivery, the use of TriMix, which contains three different mRNA encoding immune-stimulatory proteins—CD40 ligand (CD40L), CD70, and constitutively active Toll-like receptor 4 (TLR4)—as an adjuvant combined with tumor antigen-encoding mRNA was investigated [149]. The gene discussed is CD40LG; the disease is neoplasm.